PROJECT: JTC2013: HYPZITRP

New hyperforin analogues as a novel class of antidepressants with the molecular target TRPC6 channels and the interplay between TRPC6 channels, synaptic plasticity and Zinc (Zn) in the pathophysiology of depression are two new topics in depression research. These two topics are of special importance first to better understand the aetiology of depression and second to develop new strategies for the treatment of depression. The project is divided into 2 major parts so-called workpackages (WP) (WP1+2+3 vs. WP4) each of them involving at least two partners and gathering various complementary methodologies and skills. Regarding new treatment options for depressed patients two major drawbacks have to be kept in mind when considering the pharmacological treatment of mood disorders with classical antidepressants molecules: their side-effects (which can lead to the cessation of the treatment) and the high incidence of treatment-resistance patients (nearly 30% of them). Both aspects are of great importance particularly when considering the total health and economic costs of a long-term treatment or treatment failure. This application will help to better understand the complex pathophysiology of depression and to provide a novel therapeutical concept aiming to lower side-effects and to improve treatment resistance.